Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

S

SCRI Development Innovations

Status

Completed

Conditions

Metastatic Breast Cancer

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT00876070
SCRI OUTCOMES 02

Details and patient eligibility

About

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

Enrollment

198 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Patients that have received Abraxane chemotherapy greater than three months from the time of chart review.
  • Patients that have received taxane chemotherapy greater than three months from the time of chart review.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems